Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis

Tarun Kaushik, Muhammad Magdi YaqoobBarts Health NHS Trust, William Harvey Research Unit, London, UKAbstract: Peginesatide is the newest erythropoietin-stimulating agent (ESA) in the quest for the ideal treatment of anemia in chronic kidney disease (CKD) patients. Reduced frequency of administration...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kaushik T, Yaqoob MM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/44fb5b1bb52f4c109ffa20b0fc6d9b12
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:44fb5b1bb52f4c109ffa20b0fc6d9b12
record_format	dspace
spelling	oai:doaj.org-article:44fb5b1bb52f4c109ffa20b0fc6d9b122021-12-02T08:16:01ZLessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis1177-54751177-5491https://doaj.org/article/44fb5b1bb52f4c109ffa20b0fc6d9b122013-11-01T00:00:00Zhttp://www.dovepress.com/lessons-learned-from-peginesatide-in-the-treatment-of-anemia-associate-a14949https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Tarun Kaushik, Muhammad Magdi YaqoobBarts Health NHS Trust, William Harvey Research Unit, London, UKAbstract: Peginesatide is the newest erythropoietin-stimulating agent (ESA) in the quest for the ideal treatment of anemia in chronic kidney disease (CKD) patients. Reduced frequency of administration along with a possibly lower cost as a result of simpler manufacturing techniques compared with other available agents makes peginesatide a highly desirable product in the competitive ESA market. Peginesatide is noninferior to the other ESAs, and has a good safety profile in patients on hemodialysis. The higher rates of adverse cardiovascular events reported in CKD patients not on dialysis in the recent Phase III studies require further, better planned, studies. Peginesatide had to be withdrawn from the market in the US after some reports of hypersensitivity reactions to the drug. This is a setback, but the scientific advances gained as a result of this product development can be used to develop other, newer products.Keywords: anemia, hemodialysis, chronic kidney disease, peginesatideKaushik TYaqoob MMDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2013, Iss default, Pp 243-246 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Kaushik T Yaqoob MM Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
description	Tarun Kaushik, Muhammad Magdi YaqoobBarts Health NHS Trust, William Harvey Research Unit, London, UKAbstract: Peginesatide is the newest erythropoietin-stimulating agent (ESA) in the quest for the ideal treatment of anemia in chronic kidney disease (CKD) patients. Reduced frequency of administration along with a possibly lower cost as a result of simpler manufacturing techniques compared with other available agents makes peginesatide a highly desirable product in the competitive ESA market. Peginesatide is noninferior to the other ESAs, and has a good safety profile in patients on hemodialysis. The higher rates of adverse cardiovascular events reported in CKD patients not on dialysis in the recent Phase III studies require further, better planned, studies. Peginesatide had to be withdrawn from the market in the US after some reports of hypersensitivity reactions to the drug. This is a setback, but the scientific advances gained as a result of this product development can be used to develop other, newer products.Keywords: anemia, hemodialysis, chronic kidney disease, peginesatide
format	article
author	Kaushik T Yaqoob MM
author_facet	Kaushik T Yaqoob MM
author_sort	Kaushik T
title	Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
title_short	Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
title_full	Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
title_fullStr	Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
title_full_unstemmed	Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
title_sort	lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/44fb5b1bb52f4c109ffa20b0fc6d9b12
work_keys_str_mv	AT kaushikt lessonslearnedfrompeginesatideinthetreatmentofanemiaassociatedwithchronickidneydiseaseinpatientsondialysis AT yaqoobmm lessonslearnedfrompeginesatideinthetreatmentofanemiaassociatedwithchronickidneydiseaseinpatientsondialysis
_version_	1718398597244911616

Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis

Ejemplares similares